Skip to content

A comparison of bupivacaine and lidocaine for pain relief during repair of perineal tears and cut sustained during childbirth

Bupivacaine versus Lidocaine as Analgesia for Episiorrhaphy and Repair of Perineal Lacerations: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202501611433171
Enrollment
126
Registered
2025-01-17
Start date
2025-01-27
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episiotomy and Perineal lacerations/tears

Interventions

Bupivacaine
Lidocaine

Sponsors

Sanusi Akinsola Tesleem
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Parturients who had episiotomy, bleeding 1st degree and second-degree perineal lacerations following vaginal delivery. 2. Gestational age greater than 28 weeks.

Exclusion criteria

Exclusion criteria: 1. Parturients who had cervical, third- or fourth-degree perineal lacerations 2. Parturients with medical conditions that require special pain control such as sickle cell disease. 3. Parturients with major primary postpartum haemorrhage 4. Parturients with history of allergy to bupivacaine, lidocaine and pentazocine. 5. Parturients who are not fully conscious 6. Parturients who had epidural analgesia in labour

Design outcomes

Primary

MeasureTime frame
The primary outcome measures will be analgesic efficacy and the participant’s satisfaction with pain control during perineal repair and 2, 12, 24 and 48 postoperative hours.

Secondary

MeasureTime frame
The secondary outcome measures will comprise demand for additional analgesia during repair.;Time interval between infiltration of both bupivacaine or lidocaine and the participant’s first request for additional analgesia and occurrence of side effects.

Countries

Nigeria

Contacts

Public ContactRukiyat Abdussalam

Consultant

deolaabdussalam@gmail.com+2348036492782

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026